Special attention is devoted to mutated KRAS inhibitors, which probably represent the first dream come true in anti-metastatic cancer therapy of pharmacology researchers and open the way to potentially very broad therapeutic indications. Here, KRAS is linked to metastatic malignant neoplasm.